2024
Circulating tumor-reactive KIR(+)CD8(+) T cells suppress anti-tumor immunity in patients with melanoma.
Lu BY, Lucca LE, Lewis W, Wang J, Nogueira CV, Heer S, Rayon-Estrada V, Axisa PP, Reeves SM, Buitrago-Pocasangre NC, Pham GH, Kojima ML, Wei W, Aizenbud L, Bacchiocchi A, Zhang L, Walewski JJ, Chiang V, Olino K, Clune J, Halaban R, Kluger Y, Coyle AJ, Kisielow J, Obermair FJ, Kluger HM, Hafler DA. Circulating tumor-reactive KIR(+)CD8(+) T cells suppress anti-tumor immunity in patients with melanoma. Nat Immunol 2024 PMID: 39609626, DOI: 10.1038/s41590-024-02023-4.Peer-Reviewed Original ResearchDecoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti-CTLA-4 in renal cell carcinoma
Schoenfeld D, Djureinovic D, Su D, Zhang L, Lu B, Kamga L, Mann J, Huck J, Hurwitz M, Braun D, Jilaveanu L, Ring A, Kluger H. Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti-CTLA-4 in renal cell carcinoma. JCI Insight 2024 PMID: 39561007, DOI: 10.1172/jci.insight.184545.Peer-Reviewed Original ResearchAnti-CTLA-4Renal cell carcinomaIL-18IL-18BPCell carcinomaTumor microenvironmentTumor typesPatients treated with immune checkpoint inhibitorsRegulatory T cell levelsAnti-PD-1 treatmentCD8+ T cellsAnti-PD-1Immune checkpoint inhibitorsCell renal cell carcinomaNon-responder patientsMyeloid cell populationsT cell levelsCytokine interleukin-18Anti-cancer efficacySecreted binding proteinCheckpoint inhibitorsResponding patientsPreclinical modelsT cellsMurine modelHLA class-I antigen presentation machinery (APM) alterations mediate immune evasion in lung cancer brain metastases.
Vilariño N, Lopez De Rodas M, Ranjan K, Costantini A, Villalba M, Lu B, Kravitz C, Nadal E, Goldberg S, Nguyen D, Schalper K. HLA class-I antigen presentation machinery (APM) alterations mediate immune evasion in lung cancer brain metastases. Journal Of Clinical Oncology 2024, 42: e14014-e14014. DOI: 10.1200/jco.2024.42.16_suppl.e14014.Peer-Reviewed Original ResearchLung cancer brain metastasisPrimary lung tumorsTumor-infiltrating lymphocytesImmune checkpoint inhibitorsCancer brain metastasesAntigen presentation machineryB2M expressionIFN-gBrain metastasesB2MImmune evasionAssociated with shorter overall survivalMultiplexed quantitative immunofluorescenceM expressionExpression of B2MB2M levelsExpression of pSTAT1Shorter overall survivalUnfavorable clinical featuresNo significant associationAssociated with unfavorable clinical featuresCheckpoint inhibitorsImmunotherapy resistanceProperties of tumorsPresentation machineryProviding 0.1 Full-Time Equivalent (FTE) Support to Fellowship Core Faculty Improves Faculty Involvement in Fellowship Education and Recruitment
Butt A, Christian J, Kress A, Lu B, Hurwitz M, Goldberg S, Podoltsev N, Gilkes L, Lee A. Providing 0.1 Full-Time Equivalent (FTE) Support to Fellowship Core Faculty Improves Faculty Involvement in Fellowship Education and Recruitment. Journal Of Cancer Education 2024, 39: 325-334. PMID: 38430454, DOI: 10.1007/s13187-024-02414-z.Peer-Reviewed Original ResearchFull-time equivalent supportFull-time equivalentAmerican Council for Graduate Medical EducationCore facultyFellowship programsFellowship educationGraduate Medical EducationImprove job satisfactionCF programPotential unintended consequencesMedical educationSalary supportSurvey respondentsIncreased participationMedical oncologyUnintended consequencesSubspecialty fellowshipsIncreased senseSense of commitmentJob satisfactionFellowshipEducationFaculty involvement
2023
Beyond the Lab and Into the Hospital: An Outlook on the Clinical Utility of Spatial Omics Technologies
Pucciarelli D, Lu B, Zlobec I, DiStasio M. Beyond the Lab and Into the Hospital: An Outlook on the Clinical Utility of Spatial Omics Technologies. GEN Biotechnology 2023, 2: 360-371. DOI: 10.1089/genbio.2023.0030.Peer-Reviewed Original ResearchChemoimmunotherapy for Untreated Lung Cancer Brain Metastases: Systemic Before Local Therapy?
Lu B, Goldberg S. Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: Systemic Before Local Therapy? Journal Of Clinical Oncology 2023, 41: 4462-4464. PMID: 37603819, DOI: 10.1200/jco.23.01323.Peer-Reviewed Original ResearchBSBM-16 HLA CLASS-I ANTIGEN PRESENTATION MACHINERY AND IFN-γ PATHWAY ALTERATIONS IN LUNG CANCER BRAIN METASTASES
Vilarino N, de Rodas M, Lu B, Goldberg S, Schalper K. BSBM-16 HLA CLASS-I ANTIGEN PRESENTATION MACHINERY AND IFN-γ PATHWAY ALTERATIONS IN LUNG CANCER BRAIN METASTASES. Neuro-Oncology Advances 2023, 5: iii4-iii4. PMCID: PMC10402438, DOI: 10.1093/noajnl/vdad070.012.Peer-Reviewed Original ResearchLung cancer brain metastasesPrimary lung tumorsImmune checkpoint inhibitorsCancer brain metastasesBrain metastasesPresentation machineryClinicopathologic variablesHLA classTumor cell PD-L1 expressionBackground Immune checkpoint inhibitorsLocal adaptive immune responseHLA Class I AntigenPD-L1 expressionDuration of responseB2MAdaptive immune responsesDistinct immunomodulatory propertiesImmune evasion mechanismsClass I AntigenIFN-γ signalingIRF-1Interferon regulatory factor 1Checkpoint inhibitorsMost patientsWorse survivalThe Association Between Civil Legal Needs After Incarceration, Psychosocial Stress, and Cardiovascular Disease Risk Factors
Lu B, Thomas K, Feder S, Bhandary-Alexander J, Aminawung J, Puglisi L. The Association Between Civil Legal Needs After Incarceration, Psychosocial Stress, and Cardiovascular Disease Risk Factors. The Journal Of Law, Medicine & Ethics 2023, 51: 856-864. PMID: 38477262, PMCID: PMC10937168, DOI: 10.1017/jme.2024.26.Peer-Reviewed Original ResearchConceptsLegal needsCardiovascular disease risk factorsDisease risk factorsCivil legal needsIncarcerated peoplePsychosocial stressAssociated with psychosocial stressRelease peoplePublic benefitsRisk factorsHigh blood pressureHealthcare accessRe-entryHigh cholesterolIncarcerationBlood pressureNeedsAssociationPeoplePsychosocialHealthcareSocietyDebtCardiovascularHealthBeyond the Lab and Into the Hospital: An Outlook on the Clinical Utility of Spatial Omics Technologies
Pucciarelli DM, Lu BY, Zlobec I, DiStasio M. Beyond the Lab and Into the Hospital: An Outlook on the Clinical Utility of Spatial Omics Technologies. GEN Biotechnology. Oct 2023.360-371. http://doi.org/10.1089/genbio.2023.0030Commentaries, Editorials and Letters
2022
Neurological complications of lung cancer
Kaulen LD, Lu BY, Goldberg SB, Baehring JM, Chapter 15 - Neurological complications of lung cancer, Editor(s): Herbert B. Newton, Mark G. Malkin, Neurological Complications of Systemic Cancer and Antineoplastic Therapy (Second Edition), Academic Press, 2022, Pages 243-276, DOI: 10.1016/b978-0-12-821976-8.00027-xChapters
2021
Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases
Lu BY, Gupta R, Aguirre-Ducler A, Gianino N, Wyatt H, Ribeiro M, Chiang VL, Contessa JN, Adeniran AJ, Jilaveanu LB, Kluger HM, Schalper KA, Goldberg SB. Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases. Journal For ImmunoTherapy Of Cancer 2021, 9: e002684. PMID: 34670827, PMCID: PMC8529973, DOI: 10.1136/jitc-2021-002684.Peer-Reviewed Original ResearchConceptsPrimary lung tumorsT cell subsetsMajor T cell subsetsMultiplexed quantitative immunofluorescenceLung tumorsT cellsCoinhibitory receptorsTim-3Cell subsetsBrain metastasesQuantitative immunofluorescenceHigh LAG-3 expressionTumor PD-L1 expressionPD-L1 protein expressionLymphocyte activation gene-3Low T cell infiltrationHigh TIM-3Major clinicopathological variablesPD-L1 expressionLAG-3 expressionT cell infiltrationTumor-infiltrating lymphocytesLonger overall survivalCell death 1Tumor immune microenvironmentIntracranial Complications From Immune Checkpoint Therapy in a Patient With NSCLC and Multiple Sclerosis: Case Report
Lu BY, Isitan C, Mahajan A, Chiang V, Huttner A, Mitzner JR, Wesley SF, Goldberg SB. Intracranial Complications From Immune Checkpoint Therapy in a Patient With NSCLC and Multiple Sclerosis: Case Report. JTO Clinical And Research Reports 2021, 2: 100183. PMID: 34590030, PMCID: PMC8474265, DOI: 10.1016/j.jtocrr.2021.100183.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsMultiple sclerosisRadiation necrosisBrain lesionsWhole-brain radiation therapyImmune checkpoint therapyViable tumor cellsPaucity of dataBrain metastasesCheckpoint inhibitorsMetastatic NSCLCAdverse eventsCheckpoint therapyDurable responsesNeurologic declineRadiographic benefitIntracranial complicationsPathologic findingsAutoimmune disordersAutoimmune diseasesCase reportIntracranial diseaseRadiation therapyStereotactic radiosurgeryAnticancer benefits
2020
PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice
Eguren-Santamaria I, Sanmamed MF, Goldberg SB, Kluger HM, Idoate MA, Lu B, Corral J, Schalper KA, Herbst RS, Gil-Bazo I. PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice. Clinical Cancer Research 2020, 26: 4186-4197. PMID: 32354698, DOI: 10.1158/1078-0432.ccr-20-0798.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerImmune checkpoint inhibitorsAnti-PD-1/PD-L1 antibodiesAdvanced non-small cell lung cancerNSCLC brain metastasesBrain metastasesPD-L1 antibodiesAnti-PD-1/PD-L1 agentsPD-1/PD-L1 blockersActive central nervous system (CNS) involvementHigh PD-L1 expressionAnti-PD-1/PD-L1 drugsCentral nervous system involvementPivotal phase III trialsActive brain metastasesCNS response ratesPD-L1 agentsPD-L1 blockersSystemic therapy combinationsNervous system involvementPD-L1 expressionPhase III trialsSubset of patientsCell lung cancerPD-L1 drugs
2019
Functional profile and clinical significance of major tumor infiltrating lymphocyte subsets in lung cancer-associated brain metastases.
Lu B, Gupta R, Stewart T, Kluger H, Jilaveanu L, Schalper K, Goldberg S. Functional profile and clinical significance of major tumor infiltrating lymphocyte subsets in lung cancer-associated brain metastases. Journal Of Clinical Oncology 2019, 37: 2066-2066. DOI: 10.1200/jco.2019.37.15_suppl.2066.Peer-Reviewed Original ResearchPrimary lung tumorsMajor T cell subsetsMultiplexed quantitative immunofluorescenceT cell subsetsExtracranial metastasesT cellsLung tumorsBrain metastasesQuantitative immunofluorescenceAdaptive anti-tumor responsesLow T cell infiltrationMajor clinicopathologic variablesYale Cancer CenterAdaptive immune cellsRegulatory T cellsT cell infiltrationAnti-tumor responseLonger overall survivalOptimal treatment strategyLung cancer patientsKi-67 levelsLung cancer histologyLymphocyte subsetsOverall survivalPrimary malignancy
2018
Heterogeneity within the PF-EPN-B ependymoma subgroup
Cavalli FMG, Hübner JM, Sharma T, Luu B, Sill M, Zapotocky M, Mack SC, Witt H, Lin T, Shih DJH, Ho B, Santi M, Emery L, Hukin J, Dunham C, McLendon RE, Lipp ES, Gururangan S, Grossbach A, French P, Kros JM, van Veelen MC, Rao AAN, Giannini C, Leary S, Jung S, Faria CC, Mora J, Schüller U, Alonso MM, Chan JA, Klekner A, Chambless LB, Hwang EI, Massimino M, Eberhart CG, Karajannis MA, Lu B, Liau LM, Zollo M, Ferrucci V, Carlotti C, Tirapelli DPC, Tabori U, Bouffet E, Ryzhova M, Ellison DW, Merchant TE, Gilbert MR, Armstrong TS, Korshunov A, Pfister SM, Taylor MD, Aldape K, Pajtler KW, Kool M, Ramaswamy V. Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathologica 2018, 136: 227-237. PMID: 30019219, PMCID: PMC6373486, DOI: 10.1007/s00401-018-1888-x.Peer-Reviewed Original ResearchConceptsGenome-wide methylation dataPFA ependymomasChromosome 13q lossDNA methylation profilingGene expression profilesGene expression profilingCopy number profilingBroad copy-number aberrationsCopy number alterationsCopy number aberrationsMethylation profilingExpression profilingExpression profilesDistinct molecular variantsMethylation dataIntegrated analysisDistinct molecular subtypesMolecular variantsProfilingT-SNE analysisMolecular heterogeneityRobust markerPF-EPNNovel markerBiological heterogeneityPD-L1 expression and tumor-infiltrating lymphocytes in lung cancer brain metastases.
Lu B, Gupta R, Ribeiro M, Stewart T, Chiang V, Contessa J, Adeniran A, Kluger H, Jilaveanu L, Schalper K, Goldberg S. PD-L1 expression and tumor-infiltrating lymphocytes in lung cancer brain metastases. Journal Of Clinical Oncology 2018, 36: e24116-e24116. DOI: 10.1200/jco.2018.36.15_suppl.e24116.Peer-Reviewed Original Research
2016
Splice site mutation in factor X gene manifesting as severe intracranial haemorrhage in neonatal period with a challenging treatment course
Madhusoodhan P, Lu B, Chen J, Jones C, Meyer J, Roman E, Nardi M, Carroll W, Bhatla T. Splice site mutation in factor X gene manifesting as severe intracranial haemorrhage in neonatal period with a challenging treatment course. Haemophilia 2016, 23: e138-e140. PMID: 27995737, DOI: 10.1111/hae.13138.Peer-Reviewed Original ResearchDecitabine enhances chemosensitivity of early T-cell precursor-acute lymphoblastic leukemia cell lines and patient-derived samples.
Lu BY, Thanawala SU, Zochowski KC, Burke MJ, Carroll WL, Bhatla T. Decitabine enhances chemosensitivity of early T-cell precursor-acute lymphoblastic leukemia cell lines and patient-derived samples. Leukemia & Lymphoma 2016, 57: 1938-41. PMID: 26726842, DOI: 10.3109/10428194.2015.1110747.Peer-Reviewed Original ResearchFacial manifestations of Epstein–Barr virus‐related lymphoproliferative disease in childhood acute lymphoblastic leukemia in remission: Two atypical presentations
Lu B, Kojima L, Huang M, Friedmann A, Ferry J, Weinstein H. Facial manifestations of Epstein–Barr virus‐related lymphoproliferative disease in childhood acute lymphoblastic leukemia in remission: Two atypical presentations. Pediatric Blood & Cancer 2016, 63: 2042-2045. PMID: 27392033, DOI: 10.1002/pbc.26102.Peer-Reviewed Original ResearchConceptsAcute lymphoblastic leukemiaLymphoblastic leukemiaLymphoproliferative diseaseB-cell acute lymphoblastic leukemiaRight-sided facial swellingT-cell acute lymphoblastic leukemiaChildhood acute lymphoblastic leukemiaHematopoietic transplantationMaintenance chemotherapyPrimary immunodeficiencyBilateral dacryoadenitisAtypical presentationFacial swellingLip lesionsNeither patientLymphoplasmacytic infiltrationT cellsFacial manifestationsFacial lesionsB cellsPatientsDe-escalationRemissionLeukemiaLesionsDecitabine enhances chemosensitivity of early T-cell precursor-acute lymphoblastic leukemia cell lines and patient-derived samples
Lu B, Thanawala S, Zochowski K, Burke M, Carroll W, Bhatla T. Decitabine enhances chemosensitivity of early T-cell precursor-acute lymphoblastic leukemia cell lines and patient-derived samples. Leukemia & Lymphoma 2016, 57: 1938-1941. PMID: 26726842, DOI: 10.3109/10428194.2015.1110747.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsAzacitidineBasic Helix-Loop-Helix Transcription FactorsCell Line, TumorCell SurvivalDecitabineDrug SynergismGene Expression Regulation, LeukemicHumansJurkat CellsMiceNeoplasm ProteinsPrecursor T-Cell Lymphoblastic Leukemia-LymphomaReceptors, Interleukin-7Reverse Transcriptase Polymerase Chain ReactionXenograft Model Antitumor Assays